US DRUGMAKERS have raised
prices an average of 10% on
branded drugs since late Dec
according to equity analysts.
Some of these increases are
adding thousands of dollars to
already pricey drugs.
Since 01 Jan Pfizer raised list
prices an average of 10.6% on more
than 60 branded products with
prices for eight products going up
at least 20%.
Acorda Therapeutics raised the
price of its drug Ampyra used to
help multiple sclerosis patients
improve walking by 11% on 01 Jan
to an annual cost of more than
$US23,650 per patient.
Drugmakers say they need to
raise prices to fund risky research
but the price hikes shed light on
the drug companies’ pricing power
and the lack of regulatory bodies in
place to control the prices.The above article was sent to subscribers in Pharmacy Daily's issue from 12 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Jan 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.